Long-term use of psychedelic drugs is associated with differences in brain structure and personality in humans
This study (n=44) investigated the long-term effects of regular ayahuasca use on the human brain. Structural MRI showed that regular ayahuasca users had significantly different cortical thickness (with thinning in the posterior cingulate cortex) when compared to non-users. Although direct causation cannot be established, these data suggest that regular use of psychedelic drugs could potentially lead to structural changes in brain areas supporting attentional processes, self-referential thought, and internal mentation.
Authors
- Jordi Riba
- Jamie Hallak
- Sidarta Ribeiro
Published
Abstract
Psychedelic agents have a long history of use by humans for their capacity to induce profound modifications in perception, emotion and cognitive processes. Despite increasing knowledge of the neural mechanisms involved in the acute effects of these drugs, the impact of sustained psychedelic use on the human brain remains largely unknown. Molecular pharmacology studies have shown that psychedelic 5-hydroxytryptamine (5HT)2A agonists stimulate neurotrophic and transcription factors associated with synaptic plasticity. These data suggest that psychedelics could potentially induce structural changes in brain tissue. Here we looked for differences in cortical thickness (CT) in regular users of psychedelics. We obtained magnetic resonance imaging (MRI) images of the brains of 22 regular users of ayahuasca (a preparation whose active principle is the psychedelic 5HT2A agonist N,N-dimethyltryptamine (DMT)) and 22 controls matched for age, sex, years of education, verbal IQ and fluid IQ. Ayahuasca users showed significant CT differences in midline structures of the brain, with thinning in the posterior cingulate cortex (PCC), a key node of the default mode network. CT values in the PCC were inversely correlated with the intensity and duration of prior use of ayahuasca and with scores on self-transcendence, a personality trait measuring religiousness, transpersonal feelings and spirituality. Although direct causation cannot be established, these data suggest that regular use of psychedelic drugs could potentially lead to structural changes in brain areas supporting attentional processes, self-referential thought, and internal mentation. These changes could underlie the previously reported personality changes in long-term users and highlight the involvement of the PCC in the effects of psychedelics.
Research Summary of 'Long-term use of psychedelic drugs is associated with differences in brain structure and personality in humans'
Introduction
Psychedelic substances have been used across cultures to produce profound alterations in perception, emotion and cognition, and contemporary interest has focused both on their acute neural effects and their potential therapeutic uses. Molecular studies indicate that classic psychedelics acting as 5-HT2A agonists can trigger expression of immediate early genes and increase brain-derived neurotrophic factor, processes linked to synaptic plasticity; however, the long-term impact of repeated psychedelic exposure on human brain structure remains poorly characterised. Bouso and colleagues set out to test whether sustained use of a psychedelic preparation—ayahuasca—relates to differences in cortical structure and to psychometric and neuropsychological measures. They hypothesised that repeated psychedelic exposure would correlate with changes in cortical thickness and therefore compared chronic ayahuasca users with matched controls on MRI-derived cortical thickness (CT), personality, psychopathology and cognitive performance.
Expert Research Summaries
Go Pro to access AI-powered section-by-section summaries, editorial takes, and the full research toolkit.
Full Text PDF
Full Paper PDF
Create a free account to open full-text PDFs.
Study Details
- Study Typeindividual
- Journal
- Compound
- Topics
- Authors
- APA Citation
Bouso, J. C., Palhano-Fontes, F., Rodríguez-Fornells, A., Ribeiro, S., Sanches, R., Crippa, J. A. S., Hallak, J. E., de Araujo, D. B., & Riba, J. (2015). Long-term use of psychedelic drugs is associated with differences in brain structure and personality in humans. European Neuropsychopharmacology, 25(4), 483-492. https://doi.org/10.1016/j.euroneuro.2015.01.008
References (12)
Papers cited by this study that are also in Blossom
Bouso, J. C., Fábregas, J. M., Antonijoan, R. M. et al. · Psychopharmacology (2013)
Bouso, J. C., González, D., Fondevila, S. et al. · PLOS ONE (2012)
Carhart-Harris, R. L., Erritzoe, D., Williams, T. et al. · PNAS (2012)
Fábregas, J. M., González, D., Fondevila, S. et al. · Drug and Alcohol Dependence (2010)
Gonza ´lez-Maeso, J., Weisstaub, N. V., Zhou, M. et al. · Neuron (2007)
Griffiths, R. R., Johnson, M. W., Richards, W. A. et al. · Psychopharmacology (2011)
Grob, C. S., Danforth, A. L., Chopra, G. S. et al. · JAMA Psychiatry (2011)
Maclean, K. A., Johnson, M. W., Griffiths, R. R. · Journal of Psychopharmacology (2011)
Muthukumaraswamy, S. D., Carhart-Harris, R. L., Moran, R. J. et al. · Journal of Neuroscience (2013)
Riba, J., Anderer, P., Jané, F. et al. · Neuropsychobiology (2004)
Show all 12 referencesShow fewer
Riba, J., Urbano, G., Morte, A. et al. · Psychopharmacology (2001)
Vollenweider, F. X., Leenders, K. L., Maguire, P. et al. · Neuropsychopharmacology (1997)
Cited By (78)
Papers in Blossom that reference this study
Lima, G., Soares, C., Teixeira, M. et al. · Scientific Reports (2025)
Dor-Ziderman, Y., David, J., Berkovich-Ohana, A. · Psychopharmacology (2025)
Rego Ramos, L., Fernandes Jr, O., Arruda Sanchez, T. · Journal of Magnetic Resonance Imaging (2025)
Godfrey, K., Weiss, B., Zhang, X. et al. · Neuroscience Applied (2025)
Doss, M. K., Kloft, L., Mason, N. L. et al. · Journal of Psychopharmacology (2024)
Agnorelli, C., Spriggs, M. J., Godfrey, K. et al. · Preprints (2024)
Sabé, M., Sulstarova, A., Glangetas, A. et al. · Molecular Psychiatry (2024)
Olami, A., Peled-Avron, L. · Scientific Reports (2024)
Caspani, G., Ruffell, S. G. D., Tsang, WF. et al. · Pharmacological Research (2024)
Fonseca, A. M., Dos Santos, R. G., Santos, F. P. et al. · European Archives of Psychiatry and Clinical Neuroscience (2024)
Show all 78 papersShow fewer
Allen, J., Dames, S., Foldi, C. J. et al. · Molecular Psychiatry (2024)
Mallaroni, P., Mason, N. L., Kloft, L. et al. · NeuroImage (2024)
Weiss, B., Sleep, C., Beller, N. et al. · Journal of Psychedelic Studies (2023)
Greń, J., Tylš, F., Lasocik, M. et al. · Frontiers in Psychology (2023)
Mallaroni, P., Mason, N. L., Kloft, L. et al. · Frontiers in Neuroscience (2023)
Apud, I., Scuro, J., Rodríguez, L. et al. · Journal of Psychoactive Drugs (2023)
Aday, J. S., Skiles, Z., Eaton, N. et al. · Psychedelic Medicine (2023)
Brasher, T., Rosen, D., Spinella, M. · International Journal of Wellbeing (2023)
Timmermann, C., Vollenweider, F. X. · Trends in Cognitive Sciences (2023)
Bouso, J. C., Andión, O., Sarris, J. et al. · PLOS Global Public Health (2022)
Perkins, D., Pagni, B. A., Sarris, J. et al. · Frontiers in Pharmacology (2022)
Bouso, J. C., Simonsson, O., Kurth, F. et al. · Frontiers in Psychiatry (2022)
Gattuso, J. J., Perkins, D., Ruffell, S. G. D. et al. · International Journal of Neuropsychopharmacology (2022)
Ornelas, I. M., Cini, F. A., Wießner, I. et al. · Experimental Neurology (2022)
Stoliker, D., Egan, G. F., Friston, K. J. et al. · Pharmacological Reviews (2022)
Costa, M. A. · Journal of Psychoactive Drugs (2022)
Kiraga, M. K., Kuypers, K. P. C., Uthaug, M. V. et al. · Frontiers in Psychiatry (2022)
Wießner, I., Olivieri, R., Falchi, M. et al. · European Neuropsychopharmacology (2022)
Timmermann, C., Watts, R., Dupuis, D. · Transcultural Psychiatry (2022)
Stoliker, D., Novelli, L., Vollenweider, F. X. et al. · MedRvix (2021)
Olson, D. E. · Journal of Neurochemistry (2021)
Ona, G., Berrada, A., Bouso, J. C. · Transcultural Psychiatry (2021)
Kiraga, M. K., Mason, N. L., Uthaug, M. V. et al. · Frontiers in Pharmacology (2021)
Basedow, L. A., Riemer, T. G., Reiche, S. et al. · Frontiers in Pharmacology (2021)
Dos Santos, R. G., Rocha, J. M., Rossi, G. N. et al. · Frontiers in Psychiatry (2021)
Perkins, D., Opaleye, E. S., Simonová, H. et al. · Drug and Alcohol Review (2021)
Bouso, J. C., Révész, D., Ona, G. et al. · Frontiers in Psychiatry (2021)
González, D., Cantillo, J., Perez, I. et al. · Frontiers in Pharmacology (2021)
Weiss, B., Miller, J. D., Carter, N. T. et al. · Scientific Reports (2021)
Bouso, J. C., Ona, G., Dos Santos, R. G. et al. · Advances in Experimental Medicine and Biology (2021)
Nichols, D. E., Walter, H. · Pharmacopsychiatry (2020)
Johnstad, P. G. · Journal of Psychoactive Drugs (2020)
Kelly, J. R., Crockett, M. T., Alexander, L. et al. · Irish Journal of Psychological Medicine (2020)
Netzband, N., Ruffell, S., Linton, &. S. et al. · Psychopharmacology (2020)
Smith, W. R., Sisti, D. · Journal of Medical Ethics (2020)
Aday, J. S., Mitzkovitz, C. M., Bloesch, E. K. et al. · Neuroscience and Biobehavioral Reviews (2020)
Jiménez-Garrido, D. F., Gómez-Sousa, M., Ona, G. et al. · Scientific Reports (2020)
Murphy-Beiner, A., Soar, K. · Psychopharmacology (2020)
Dos Santos, R. G., Hallak, J. E. · Neuroscience and Biobehavioral Reviews (2020)
Carhart-Harris, R. L., Friston, K. J. · Pharmacological Reviews (2019)
Cameron, L. P., Benson, C. J., Defelice, B. C. et al. · ACS Chemical Neuroscience (2019)
Ona, G., Kohek, M., Massaguer, T. et al. · Journal of Psychoactive Drugs (2019)
Stenbæk, D. S., Kristiansen, S., Burmester, D. et al. · Human Brain Mapping (2019)
Mello, S. M., Soubhia, P. C., Silveira, G. et al. · Journal of Psychoactive Drugs (2018)
Barker, S. · Frontiers in Neuroscience (2018)
Jungaberle, H., Thal, S., Zeuch, A. et al. · Neuropharmacology (2018)
Carhart-Harris, R. L. · Neuropharmacology (2018)
Swanson, L. R. · Frontiers in Pharmacology (2018)
Adams, T. · Biorxiv (2018)
Carhart-Harris, R. L., Roseman, L., Bolstridge, M. et al. · Scientific Reports (2017)
Dakic, V., Nascimento, J. M., Sartore, R. C. et al. · Scientific Reports (2017)
Winkelman, M. J. · Frontiers in Neuroscience (2017)
Argento, E., Strathdee, S. A., Tupper, K. et al. · BMJ Open (2017)
Elsey, J. W. B. · Drug Science Policy and Law (2017)
Sampedro, F., de la Fuente Revenga, M., Valle, M. et al. · International Journal of Neuropsychopharmacology (2017)
Dos Santos, R. G., Hallak, J. E. · Journal of Psychoactive Drugs (2016)
Dos Santos, R. G., Osório, F. L., Crippa, J. A. et al. · Neuroscience and Biobehavioral Reviews (2016)
Sweat, N. W., Bates, L. W., Hendricks, P. S. · Journal of Psychoactive Drugs (2016)
Domínguez-Clavé, E., Soler, J., Elices, M. et al. · Brain Research Bulletin (2016)
Garcia-Romeu, A., Kersgaard, B., Addy, P. H. · Experimental and Clinical Psychopharmacology (2016)
Tófoli, L. F., De Araujo, D. B. · International Review of Neurobiology (2016)
Kuypers, K. P. C., Riba, &. J., De La Fuente Revenga, &. M. et al. · Psychopharmacology (2016)
Nunes, A. A., Dos Santos, R. G., Osório, F. L. et al. · Journal of Psychoactive Drugs (2016)
Nichols, D. E. · Pharmacological Reviews (2016)
Dos Santos, R. G., Osório, F. L., Crippa, J. A. et al. · Therapeutic Advances in Psychopharmacology (2016)
Dos Santos, R. G., Osório, F. L., Crippa, J. A. et al. · brazilian Journal of Psychiatry (2016)
Carhart-Harris, R. L., Kaelen, M., Bolstridge, M. et al. · Psychological Medicine (2016)
Alonso, J. N., Romero, S., Mañanas, M. A. et al. · International Journal of Neuropsychopharmacology (2015)
Your Personal Research Library
Go Pro to save papers, add notes, rate studies, and organize your research into custom shelves.